DARE BIOSCIENCE INC. - COMMON STOCK

Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant

20 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

06 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

09 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)

16 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

10 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

04 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

14 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites

13 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

07 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health

23 Oct 2024 11:30:00 By Nasdaq GlobeNewswire